Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Seropositive Rheumatoid Arthritis Drug Companies

ID: MRFR/Pharma/4123-HCR
90 Pages
Vikita Thakur
Last Updated: February 16, 2025
Seropositive rheumatoid arthritis refers to a form of rheumatoid arthritis where individuals test positive for certain antibodies, such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs). Drug companies play a crucial role in developing and providing medications to manage symptoms and slow the progression of seropositive rheumatoid arthritis.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Seropositive Rheumatoid Arthritis Drug Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)4.93%
2024 Market Size$ 20.61 Billion
2025 Market Size$ 21.63 Billion
2035 Market Size$ 34.99 Billion
Key Players
AbbVie
Roche
Pfizer
Johnson & Johnson
Bristol-Myers Squibb
Amgen
Opportunities
  • Advancements in Biologic Therapies
  • Increased Focus on Personalized Medicine
  • Regulatory Support for New Drug Approvals

Top Industry Leaders in the Seropositive Rheumatoid Arthritis Drug Market

Seropositive Rheumatoid Arthritis Drug Market
 

Latest Seropositive Rheumatoid Arthritis Drug Companies Updates:

AbbVie receives FDA approval for Rinvoq® (upadacitinib) for the treatment of active adult psoriatic arthritis, expanding its reach beyond rheumatoid arthritis: This approval strengthens

AbbVie's position in the autoimmune disease treatment landscape.

Pfizer announces positive Phase 3 trial results for Xeljanz® (tofacitinib) in combination with methotrexate for the treatment of active psoriatic arthritis: These results further demonstrate the potential of Xeljanz as an effective treatment option for this condition.

Roche launches Tecentriq® (atezolizumab) in combination with methotrexate for the treatment of adult patients with moderate-to-severe rheumatoid arthritis who have had an

inadequate response to one or more DMARDs: This represents a significant step forward in immunotherapy options for rheumatoid arthritis.

List of Seropositive Rheumatoid Arthritis Drug Key companies in the market:

  • Abbott Laboratories (U.S.)
  • Johnson & Johnson Limited (U.S.)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (U.S.)
  • Eli Lilly and Company (U.S.)
  • AbbVie Inc. (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)